Ono, Numab to discover multispecific antibody

Numab Therapeutics AG (Waedensil, Switzerland) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights to develop and commercialize a multispecific immuno-oncology antibody to be identified using Numab’s discovery platform. Ono also received an option to acquire IP rights to the compound.

Numab will receive R&D funding and is eligible for CHF258 million ($261.9 million) in an upfront payment and milestones, plus tiered single to double digit royalties...